Editas medicine, inc. (EDIT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flow from operating activities
Net loss

-37,724

-37,770

-32,941

-33,786

-29,249

-25,055

-15,238

-38,722

-30,939

-36,189

-26,599

-26,439

-31,097

-39,376

-21,020

-19,042

-17,745

-12,633

-7,405

-47,571

-5,291

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

6,220

6,336

6,559

6,493

7,855

6,347

6,699

7,024

6,528

8,077

4,467

5,016

5,804

3,782

3,690

5,199

4,210

1,951

1,057

440

65

Depreciation

798

752

727

693

628

926

839

784

751

734

684

651

631

488

281

246

187

148

132

108

83

Unrealized gain on corporate equity securities

7,333

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest related to facility lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

15

13

Non-cash research and development expenses

-

-

-

-

-

0

0

12,500

1,942

9,500

0

0

5,000

-

-

-

-

-

-

-

-

Re-measurement of warrant to purchase redeemable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

87

-

-

-

-

Change in fair value of preferred stock tranche asset or liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

35,478

73

Changes in fair value of anti-dilutive protection liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,583

26

Changes in deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24

-26

-21

Other non-cash items, net

215

501

468

778

1,181

1,139

1,031

668

430

283

193

-107

-69

-604

-110

-110

-45

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

1,414

107

299

12

-30

-13

-319

-569

252

-16

-125

-125

857

-1,034

-73

87

89

-

-

-

-

Prepaid expenses and other current assets

1,995

758

38

488

-789

1,061

935

653

761

338

-228

972

-486

-361

80

499

1,088

520

38

-43

-142

Right-of-use assets

-1,739

11,080

204

-1,003

-981

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

-93

-

-

-

-

-

-

-

-

0

0

0

-2

-11

-11

24

-2,248

-

-

-

-

Accounts payable

4,767

-731

2,464

-2,085

626

113

683

-4,111

5,095

-4,078

-803

-6,712

10,078

1,156

-2,164

3,715

544

-356

-5,580

6,112

-1,612

Accrued expenses

-13,644

13,976

136

2,296

-6,923

1,698

312

3,284

-1,252

628

-2,762

4,339

-10,539

7,807

1,900

320

1,814

2,703

540

-580

863

Deferred revenue

-4,309

58,323

-3,549

2,682

-2,061

18,501

511

7,019

-3,142

-3,127

-3,103

-2,277

90,214

456

158

163

158

-

-

-

-

Operating lease liabilities

-1,902

11,431

218

-946

-1,379

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current and non-current liabilities

833

1,124

525

-878

881

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-54,086

41,024

-26,884

-25,806

-29,003

1,327

-7,841

-16,733

-22,460

-25,069

-27,977

-26,162

69,791

-13,677

-17,041

-9,899

-9,629

-8,008

-11,940

20,448

-5,943

Purchases of property and equipment

2,152

1,691

2,245

1,513

718

1,415

938

1,390

1,011

289

752

362

656

676

713

1,161

943

401

190

535

305

Proceeds from the sale of equipment

-

66

0

0

36

19

13

0

5

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

66,384

37,057

198,557

31,877

74,692

108,208

126,697

171,791

52,674

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

115,000

46,500

78,500

109,500

126,000

101,000

114,000

101,500

94,500

-

-

-

-

-

-

-

-

-

-

-

-

Changes in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,619

-

-

-

-

Net cash provided by investing activities

46,464

7,818

-122,302

76,110

50,626

-8,604

-13,622

-71,681

40,820

26,678

-28,847

-180,985

-656

963

-713

-1,161

-2,562

-401

-190

-535

-305

Proceeds from equipment loan, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

709

0

791

Proceeds from offering of common stock, net of issuance costs

-

-

-

-

-

28,318

0

-3

48,474

57,458

0

-417

97,102

0

-196

-498

98,182

-

-

-

-

Proceeds from exercise of stock options

3,047

9,107

2,137

2,086

1,533

1,952

1,451

2,515

4,410

1,220

45

55

435

22

174

4

33

-

-

-

-

Payments on construction financing lease obligation

-

-

-

-

-

236

211

207

203

199

175

-53

443

-

-

-

-

-

-

-

-

Net cash provided by financing activities

3,047

84,569

43,353

2,369

1,533

30,352

1,240

2,667

52,681

58,479

-730

-309

97,094

-538

-22

-494

98,215

-3,752

120,391

21,961

791

Net (decrease) increase in cash, cash equivalents, and restricted cash

-4,575

133,411

-105,833

52,673

23,156

23,075

-20,223

-85,747

71,041

60,088

-57,554

-207,456

166,229

-13,252

-17,776

-11,554

86,024

-12,161

108,261

41,874

-5,457

Supplemental disclosure of cash and non-cash activities:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

47

99

104

96

95

Fixed asset additions included in accounts payable and accrued expenses

705

-44

676

-260

356

-17

305

242

129

389

143

84

7

-114

-20

-262

526

-

-

-

113

Cash paid in connection with operating lease liabilities

2,538

1,366

1,515

1,365

1,724

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange of operating lease obligations

-

0

0

0

19,461

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adjustment to deferred revenue for revenue adoption

-

-

-

-

-

-

0

0

474

-

-

-

-

-

-

-

-

-

-

-

-

Accrual of final payment fee on equipment loan and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

2

30

Offering expenses included in accounts payable and accrued expenses

-

-

-

-

-

70

0

3

19

-

-

-

397

-

-

-301

497

-

-

-

-

Reclassification of warrants to additional paid in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

376

-

-

-

-

Conversion of preferred stock to common stock upon closing of the initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

47

0

0

199,915

-

-

-

-

Reclassification of liability for common stock subject to repurchase

-

-

-

-

-

0

0

1

3

2

3

3

3

3

2

3

3

-

-

-

-

Issuance of common stock for settlement of success payments (see note 7)

-

-

-

-

-

-

-12,500

12,500

9,530

-

-

-

-

-

-

-

-

-

-

-

-